MiR-29 promotes ovarian carcinoma cell proliferation through the PTEN pathway
Qianqian Tang, Shi Wan, Qiao Xiao-gai, Fang Wang, Yan Wang, P Munksgaard, J Blaakaer, D Jelovac, D Armstrong, W Mcguire, W Hoskins, M Brady, P Kucera, E Partridge, K Look, D Clarke-Pearson, M Davidson, Z Gal, E Olh, S Lin, L Pan, S Guo, J Wu, L Jin, J Wang, F Kalinowski, R Brown, C Ganda, K Giles, M Epis, J Horsham, Z Wu, X Huang, X Huang, Q Zou, Y Guo, M Lv, Z Zhong, M Huang, Q Tian, R Jiang, J Chen, J Kwon, J Willy, K Quirin, R Wek, M Korc, X Yin, C Boosani, D Agrawal, Z Gao, J Wang, D Chen, X Ma, Y Wu, Z Tang, P Wang, Q Guan, D Zhou, Z Yu, Y Song, W Qiu, V Guarneri, F Piacentini, E Barbieri, P Conte, G Ferrandina, M Ludovisi, D Lorusso, S Pignata, E Breda, A Savarese, Bokkel Ten, W Huinink, S Lane, G Ross, P Rose, J Blessing, A Mayer, H Homesley, X Yang, F Liu, Y Zhang, L Wang, Y Cheng, F Farina, A Inguscio, P Kunderfranco, A Cortesi, L Elia, M Quintavalle, P Muluhngwi, N Alizadeh-Rad, S Vittitow, T Kalbfleisch, C Klinge, S To, A Mak, Eva Fung, Y Che
Abstract
The objective of this study was to investigate the role of miR-29 in ovarian carcinoma progression. Cell proliferation was measured with a cell counter. mRNA expression of miR-29, phosphatase and tensin homolog (PTEN), and proliferating cell nuclear antigen (PCNA) was measured by RT-PCR. Protein expression was detected by Western blot. The results demonstrated that miR-29 expression was upregulated in ovarian carcinoma and that miR-29 promoted cell proliferation. Consistently, miR-29 silencing decreased ovarian carcinoma cell proliferation. Mechanistically, we found PTEN expression was decreased following miR-29 overexpression and PTEN expression was increased following miR-29 silencing. Importantly, overexpression of PTEN was sufficient to inhibit ovarian carcinoma cell proliferation, demonstrating a key role for PTEN downstream of miR-29. Therefore, our study highlights the miR-29-PTEN pathway as a critical mediator of ovarian cancer cell proliferation, providing a new therapeutic target for patients with ovarian carcinoma.